Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Issue 11 (November 2013)

• Record Type: Journal Article
• Authors: Liu, Xiaoliu; Zhang, Guangsen; Yi, Yan; Xiao, Le; Pei, Minfei; Liu, Sufang; Luo, Yunya; Zhong, Haiying; Xu, Yunxiao; Zheng, Wenli; Shen, Jiankai
• Is Part Of: Leukemia & lymphoma. Volume 54:Issue 11(2013:Nov.)
• Page Start: 2466
• Page End: 2473
• Publication Date: 2013-11
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2013.778408
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>The clinical significance and mechanisms of <italic>TET2</italic> are not well defined in myeloid malignancies. We detected <italic>TET2</italic> mutations and assayed its catalyzing conversion product 5-hydroxymethylcytosine (5-hmC) in 61 Chinese patients with MDS. Ten patients were identified to have <italic>TET2</italic> mutations (16.4%). 5-hmC levels in patients with MDS with <italic>TET2</italic> mutations were significantly lower than in those without mutations, and CD34+ cells of patients with MDS exhibited a lower 5-hmC content than that of controls. <italic>TET2</italic> expression and 5-hmC in patients with MDS with <italic>P15</italic> methylation were both significantly lower than in those without <italic>P15</italic> methylation. We did not observe a correlation between <italic>TET2</italic> mutations and overall survival (OS) in MDS. Interestingly, we found that patients with MDS with higher 5-hmC levels or in lower risk groups of the Revised International Prognostic Scoring System (IPSS-R) had a longer overall survival, suggesting that 5-hmC levels may be a new molecular marker for prognostic assessment of MDS and that revised IPSS criteria are also applicable to the risk categories of Chinese patients with MDS.</p> </abstract>